Douglas D. Richardson

Douglas D. Richardson

Auto-generated profile, based on publicly available information

Douglas D. Richardson

Merck & Co., Inc

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2021 in Analytical Chemistry
Verified
Journal Article
Closed access
XLXuanwen Li
Xuanwen Li
DCDivya Chandra
Divya Chandra
SLSimon Letarte
Simon Letarte
GAGregory C. Adam
Gregory C. Adam
JWJonathan Welch
Jonathan Welch
DRDouglas D. Richardson
Douglas D. Richardson

12 March 2021 in Journal of the American Society for Mass Spectrometry
Verified
Journal Article
Open access
TMTrina Mouchahoir
Trina Mouchahoir
JSJohn E. Schiel
John E. Schiel
RRRich Rogers
Rich Rogers
AHAlan Heckert
Alan Heckert
BPBenjamin J. Place
Benjamin J. Place
HYHua Yuan
Hua Yuan
The Multi-Attribute Method (MAM) Consortium was initially formed as a venue to harmonize best practices, share experiences, and generate innovative methodologies to facilitate widespread integration of the MAM platform, which is an emerging ultra-high-performance liquid chromatography–mass spectrometry application. Successful implementation of MAM as a purity-indicating assay requires new peak detection (NPD) of potential process- and/or product-related impurities. The NPD interlaboratory study described herein was carried out by the MAM Consortium to report on the industry-wide performance of NPD using predigested samples of the NISTmAb Reference Material 8671. Results from 28 participating laboratories show that the NPD parameters being utilized across the industry are representative of high-resolution MS performance capabilities. Certain elements of NPD, including common sources of variability in the number of new peaks detected, that are critical to the performance of the purity function of MAM were identified in this study and are reported here as a means to further refine the methodology and accelerate adoption into manufacturer-specific protein therapeutic product life cycles.

1 January 2022 in Antibody Therapeutics
Verified
Journal Article
Open access
PDF file
XLXuanwen Li
Xuanwen Li
FWFengqiang Wang
Fengqiang Wang
HLHong Li
Hong Li
DRDouglas D Richardson
Douglas D Richardson
DRDavid J Roush
David J Roush
Nonionic surfactant polysorbates, including PS-80 and PS-20, are commonly used in the formulation of biotherapeutic products for both preventing surface adsorption and acting as stabilizer against protein aggregation. Trace levels of residual host cell proteins (HCPs) with lipase or esterase enzymatic activity have been shown to degrade polysorbates in biologics formulation. The measurement and control of these low abundance, high-risk HCPs for polysorbate degradation are an industry-wide challenge to achieve desired shelf life of biopharmaceuticals in liquid formulation, especially for high-concentration formulation product development. Here, we reviewed the challenges, recent advances, and future opportunities of analytical method development, risk assessment, and control strategies for polysorbate degradation during formulation development with a focus on enzymatic degradation. Continued efforts to advance our understanding of polysorbate degradation in biologics formulation will help develop high-quality medicines for patients.

21 August 2018 in mAbs
Verified
Journal Article
Open access
BPBhumit A. Patel
Bhumit A. Patel
AGAdrian Gospodarek
Adrian Gospodarek
MLMichael Larkin
Michael Larkin
SKSophia A. Kenrick
Sophia A. Kenrick
MHMark A. Haverick
Mark A. Haverick
DRDouglas D. Richardson
Douglas D. Richardson
For many protein therapeutics including monoclonal antibodies, aggregate removal process can be complex and challenging. We evaluated two different process analytical technology (PAT) applications that couple a purification unit performing preparative hydrophobic interaction chromatography (HIC) to a multi-angle light scattering (MALS) system. Using first principle measurements, the MALS detector calculates weight-average molar mass, Mw and can control aggregate levels in purification. The first application uses an in-line MALS to send start/stop fractionation trigger signals directly to the purification unit when preset Mw criteria are met or unmet. This occurs in real-time and eliminates the need for analysis after purification. The second application uses on-line ultra-high performance size-exclusion liquid chromatography to sample from the purification stream, separating the mAb species and confirming their Mw using a µMALS detector. The percent dimer (1.5%) determined by the on-line method is in agreement with the data from the in-line application (Mw increase of approximately 2750 Da). The novel HIC-MALS systems demonstrated here can be used as a powerful tool for real-time aggregate monitoring and control during biologics purification enabling future real time release of biotherapeutics.

26 December 2019 in mAbs
Verified
Journal Article
Open access
ZDZachary D. Dunn
Zachary D. Dunn
JDJayesh Desai
Jayesh Desai
GLGabriel M. Leme
Gabriel M. Leme
DSDwight R. Stoll
Dwight R. Stoll
DRDouglas D. Richardson
Douglas D. Richardson
The success of monoclonal antibody (mAb) therapeutics have increased pharmaceutical investment in mAb production, which has led to a greater demand of technologies to efficiently characterize these biotherapeutics. The large size and heterogeneity of mAbs require the measurement of multiple critical quality attributes (CQAs) during production. The current workflow to measure CQAs of antibodies involves multiple one-dimensional liquid chromatography methods, including Protein-A (ProA), ion-exchange (IEX), reversed-phase, size exclusion (SEC), hydrophilic interaction, and hydrophobic interaction (HIC). Recent advances in commercial two-dimensional liquid chromatography (2D-LC) affords an opportunity to perform two separations at once to measure multiple CQAs in a single assay. Here, we describe the development of a 2D ProA–SEC method using entirely commercially available instrumentation. Each individual separation and the transfer of material between dimensions were optimized to develop a method that measures titer and aggregation of a target antibody from harvested cell culture fluid in under 5 min. We determined the effects of each parameter of the method on mAb recovery and stability, as well as speed, robustness, resolution, and accuracy of the aggregate amount detected in the second dimension (2D). While there are still sources of error caused by hardware limitations, our rapid ProA-SEC method is an effective screening tool with a significant throughput advantage over previously described methods. Additionally, this work serves as a basis for developing other 2D-LC methods with ProA as the first dimension (1D) separation coupled with different 2D separation, such as ProA-IEX and ProA-HIC.

28 November 2022 in Analytical Chemistry
Verified
Journal Article
Closed access
RBRodell C. Barrientos
Rodell C. Barrientos
GLGioacchino Luca Losacco
Gioacchino Luca Losacco
MAMohammadmehdi Azizi
Mohammadmehdi Azizi
HWHeather Wang
Heather Wang
ANAnh Nguyet Nguyen
Anh Nguyet Nguyen
IAImad A. Haidar Ahmad
Imad A. Haidar Ahmad